COMPASS Pathways plc (NASDAQ:CMPS) Receives Average Rating of “Buy” from Analysts

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have earned a consensus rating of “Buy” from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $33.60.

Several research analysts have recently commented on the company. HC Wainwright reduced their target price on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Maxim Group reduced their price objective on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Royal Bank of Canada decreased their price objective on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research note on Monday, September 9th.

COMPASS Pathways Stock Performance

NASDAQ CMPS opened at $4.14 on Friday. The firm’s fifty day moving average price is $4.86 and its two-hundred day moving average price is $6.13. COMPASS Pathways has a 1 year low of $3.86 and a 1 year high of $12.75. The firm has a market capitalization of $283.26 million, a P/E ratio of -1.88 and a beta of 2.25. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15.

COMPASS Pathways (NASDAQ:CMPS) last issued its earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.04. During the same quarter last year, the company earned ($0.67) earnings per share. As a group, research analysts anticipate that COMPASS Pathways will post -2.33 EPS for the current year.

Hedge Funds Weigh In On COMPASS Pathways

Institutional investors and hedge funds have recently modified their holdings of the business. Blue Trust Inc. acquired a new stake in COMPASS Pathways in the 2nd quarter worth about $81,000. Green Alpha Advisors LLC acquired a new stake in shares of COMPASS Pathways in the third quarter valued at approximately $99,000. Y Intercept Hong Kong Ltd bought a new stake in shares of COMPASS Pathways in the third quarter valued at approximately $131,000. Fore Capital LLC acquired a new stake in COMPASS Pathways during the second quarter worth approximately $181,000. Finally, Geode Capital Management LLC increased its stake in COMPASS Pathways by 160.3% during the 3rd quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock worth $266,000 after acquiring an additional 25,970 shares during the period. 46.19% of the stock is currently owned by institutional investors and hedge funds.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.